Navigation Links
Accera in Medical News

Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain

...n often appear 10 to 20 years earlier than other AD symptoms, targeting them may allow for earlier treatment of the disease. Based on this hypothesis, accera is developing the AD drug, Ketasyn(TM) (AC-1202), which provides glucose-deprived brain cells with an alternative energy source. Ketasyn is converted ...

A Milky Alternative to Alzheimer Drug

...togenic diet sometimes used for children with severe epilepsy. Manufacturer accera is currently hunting funding for a Phase III study, and exploring different...ned Dr. Lauren Constantini, a former Harvard scientist now with the company accera Inc. that is developing the drug. To stop Alzheimer's brain decay,...
Accera in Medical Technology

Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study

...w and similar between Ketasyn and placebo groups. accera recently completed a Phase IIb clinical trial in A...e for efficacy in cognition and short-term memory. accera plans to initiate a pivotal, Phase III multi-cente...r's disease and Age- Associated Memory Impairment. accera has other small molecule compounds in its product ...

Accera, Inc. to Present Results of Phase II Study in Alzheimer's Disease at American Academy of Neurology Meeting

... BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- accera Inc. announced today that topline data from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) will be presented at the annu...

Accera, Inc. Announces Results of Phase II Study in Alzheimer's Disease at American Academy of Neurology Meeting

... BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- accera Inc. is presenting topline data today from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) at the American Academy of Neu...
Accera in Biological Technology

Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

BROOMFIELD, Colo., March 2 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, today launched Axona(TM) in the United States for Alzheimer's disease (AD). Axona is a first-in-class medical food for the clinical dietary...

Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease

...ona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease. accera engages in research, development and commercialization of other clinical applications for Axona. For more information about Accera, please v...

Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

... a wholly owned subsidiary and will be spun out of accera as a stand-alone company after the completion of a $12 million series A financing round. Existing accera investors have already committed to participate in...ompany, and the current small molecule pipeline at accera including the preclinical compounds, AC-0523 and A...

Accera, Inc. to Present at Upcoming Investor Conferences

...d-to-moderate Alzheimer's disease. Dr. Orndorff will provide an overview of accera and its technology pipeline and also provide an update on the successful na...ve, well-tolerated treatments. Through its proprietary scientific platform, accera is developing therapies that address metabolic deficiencies by providing an...

Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors

... impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy sourc...

Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference

...f, Ph.D., Accera's founder and CEO. "As a company focused on CNS disorders, accera is committed to improving the care and quality of life of Alzheimer's patie...ive, well-tolerated therapies. Through its proprietary scientific platform, accera is developing products that address metabolic deficiencies associated with ...

Accera, Inc. Completes $35 Million Series C Financing

...estament to the confidence of our investors in the accera organization and the potential of Axona". Wolfga... a new approach to neurodegenerative diseases, and accera is a clear leader. We are pleased to support the c...pies. Through its proprietary scientific platform, accera is developing products that address metabolic defi...

Accera, Inc. Names William T. Poncy Vice President of Commercial Development

... BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- accera Inc., a privately held biotechnology company focus...Ketasyn's excellent safety and efficacy will allow accera to make a competitive entry into the multi billion... (AD) and age-associated memory impairment (AAMI). accera plans to self-commercialize Ketasyn as a medical f...

Accera, Inc. to Present at the 4th Annual BIO Investor Forum

... BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- accera Inc., a privately held biotechnology company focused on developing novel dr... October 11 at 11:00 a.m. PDT. Dr. Orndorff will provide an overview of accera and its technology platform as well as a summary of the positive data from ...
Other Tags
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... the answer to one open-ended question predicted the teenagers, offending ... think you,ll live?", According to the study, having little hope ... Piquero said the study found those who don,t view a ... rates and commit more serious offenses, while those who believe ... less., "In a lot of distressed communities and for a ...
(Date:4/14/2014)... A new study identifies a molecule that is ... that the molecule could be an important target for ... progression. , The study of microRNA-135b (miR-135b) in two ... journal Cancer Cell and was led by ... Arthur G. James Cancer Hospital and Richard J. ...
(Date:4/14/2014)... CHICAGO --- Depression can hit young fathers hard -- with ... of their children,s lives, a new Northwestern Medicine study has ... over the first five years of fatherhood for these young ... fathers and whom lived in the same home as their ... in the journal Pediatrics . , This study is ...
(Date:4/14/2014)... around the world, many people live and work in ... block sunlight. And as the global population continues to ... will only spread. , To alleviate the problem, ... redirects sunlight onto narrow streets and alleyways. The panel ... at an angle, where it spreads sunlight onto the ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
(Date:4/15/2014)... (April 15, 2014) The American Association of ... winners. All awards will be presented during the ... Marriott Hotel on Tuesday, April 29th at 7:30 p.m. ... , The 2014 award winners are: ... Laitman, PhD, of the Icahn School of Medicine at ...
(Date:4/15/2014)... are many viral diseases in the world for which ... fever, which is spread by mosquitoes in the tropics, ... more familiar in Finland and is easily spread by ... children and the elderly. , Researchers at Aalto University ... in preliminary tests to prevent the spread of one ...
(Date:4/15/2014)... of cuttlefish, squid and octopus has uncovered details ... how they may help in investigating populations of ... described 10 new parasite species− dicyemid mesozoans −, ... squid and octopus). They are the very ... waters. , "Although dicyemid parasites have been ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Bizarre parasite may provide cuttlefish clues 2
Other Contents